EADV 2019
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/01/C2_MCR-2019-EADV_cover-1-225x300.png)
Read the full Report (pdf)
European Academy of Dermatology and Venereology 9-13 October 2019, Madrid, Spain
Featured articles
CONTENTS
Online First
Late-Breaking News
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/12/Figure-_4_mg_Baricitinib_resulted_in_a_significantly.png)
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Emerging Therapies
Small molecules: interesting novel treatment options in AD
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/12/Figure-_80__of_patients_achieved_a_______4_points_reduction.png)
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/10/Figure-_Week_12_efficacy_outcomes_among_patients-1024x413.png)
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/10/Figure-_Summary_of_efficacy_results_at_week_24.png)
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Urticaria
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/10/Table-_2019_ROSCO_guidance_for_treatment_of_rosacea_by_a_feature-driven_approach-1024x432.png)
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/10/Figure-_Improvements_in_PASI_of_the_head_and_neck_region_through_weeks.png)